The invention is based on the finding that amyloid ß (Aß) is nitrated at tyrosine 10 in AD-brains. Nitration accel-erates its aggregation and is present in Aß plaques. Injection of the nitrated protein into the brain of APP/PS1 transgenic mice leads to ß-amyloidosis.
An antibody specific to the nitrated form of Aß has been developed.
A therapeutic approach interfering with the nitrated Aß (rather than with the native Aß-peptide) may provide a very specific treatment with a reduced risk of side-effects.
Commercial Opportunities: The invention offers a novel approach for an early diagnosis of AD. The invention also opens new avenues for developing either NCEs or biologicals interfering with the nitrated Aß. Antibody-based therapeutic approaches (e.g. passive/active vaccination) are currently been developed. Prophylactic approaches are also conceivable. On behalf of University of Bonn, PROvendis offers access to rights for commercial use as well as the opportunity for further co-development.
Weitere Informationen: PDF
Tel.: +49 (0)208/94105 10
Dipl.-Ing. Alfred Schillert
email@example.com | TechnologieAllianz e.V.
System zum Schleusen, Dosieren und Spritzgießen von Material
19.01.2017 | TechnologieAllianz e.V.
Highly conductive pastes for printable electronic applications and devices
18.01.2017 | TechnologieAllianz e.V.
20.01.2017 | Veranstaltungen
19.01.2017 | Veranstaltungen
18.01.2017 | Veranstaltungen